“ALX Oncology’s ASPEN-06 Phase 2 Trial: Evorpacept Proves Promising for Patients with HER2-Positive Cancer”
ALX Oncology Announces Positive Data from ASPEN-06 Phase 2 Clinical Trial Exciting News for Cancer Treatment SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives,…